Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants
Nattokinase (NK), known as a potent fibrinolytic and antithrombotic agent, has been shown to have antiatherosclerotic and lipid-lowering effects. However, data on human clinical studies are limited. In this clinical study involving 1,062 participants, our objective was to examine the efficacy of NK...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.964977/full |
| _version_ | 1797985296072048640 |
|---|---|
| author | Hongjie Chen Jiepeng Chen Fuping Zhang Yuanhui Li Ronghua Wang Qiang Zheng Xu Zhang Jun Zeng Feng Xu Yiguang Lin Yiguang Lin Yiguang Lin |
| author_facet | Hongjie Chen Jiepeng Chen Fuping Zhang Yuanhui Li Ronghua Wang Qiang Zheng Xu Zhang Jun Zeng Feng Xu Yiguang Lin Yiguang Lin Yiguang Lin |
| author_sort | Hongjie Chen |
| collection | DOAJ |
| description | Nattokinase (NK), known as a potent fibrinolytic and antithrombotic agent, has been shown to have antiatherosclerotic and lipid-lowering effects. However, data on human clinical studies are limited. In this clinical study involving 1,062 participants, our objective was to examine the efficacy of NK in atherosclerosis and hyperlipidemia and safety at the dose of 10,800 FU/day after 12 months of oral administration. Various factors, including lower doses that influence NK pharmacological actions, were also investigated. We found that NK at a dose of 10,800 FU/day effectively managed the progression of atherosclerosis and hyperlipidemia with a significant improvement in the lipid profile. A significant reduction in the thickness of the carotid artery intima-media and the size of the carotid plaque was observed. The improvement rates ranged from 66.5 to 95.4%. NK was found to be ineffective in lowering lipids and suppressing atherosclerosis progression at a dose of 3,600 FU/day. The lipid-lowering effect of NK was more prominent in subjects who smoked, drank alcohol, and subjects with higher BMI. Regular exercise further improved the effects of NK. Co-administration of vitamin K2 and aspirin with NK produced a synergetic effect. No noticeable adverse effects associated with the use of NK were recorded. In conclusion, our data demonstrate that atherosclerosis progression and hyperlipidemia can be effectively managed with NK at a dose of 10,800 FU/day. The lower dose of 3,600 FU per day is ineffective. The dose of 10,800 FU/day is safe and well tolerated. Some lifestyle factors and the coadministration of vitamin K2 and aspirin lead to improved outcomes in the use of NK. Our findings provide clinical evidence on the effective dose of NK in the management of cardiovascular disease and challenge the recommended dose of 2,000 FU per day. |
| first_indexed | 2024-04-11T07:15:51Z |
| format | Article |
| id | doaj.art-b316ca36d630474d930757fa45a8924b |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-11T07:15:51Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-b316ca36d630474d930757fa45a8924b2022-12-22T04:38:00ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-08-01910.3389/fcvm.2022.964977964977Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participantsHongjie Chen0Jiepeng Chen1Fuping Zhang2Yuanhui Li3Ronghua Wang4Qiang Zheng5Xu Zhang6Jun Zeng7Feng Xu8Yiguang Lin9Yiguang Lin10Yiguang Lin11Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaSungen Bioscience Co. Ltd., Shantou, ChinaDepartment of Pharmacy, Shenyang Red Cross Hospital, Shenyang, ChinaGuangzhou Center, Sinopharm Group Pharmaceutical Co., Ltd., Guangzhou, ChinaSungen Bioscience Co. Ltd., Shantou, ChinaSungen Bioscience Co. Ltd., Shantou, ChinaSungen Bioscience Co. Ltd., Shantou, ChinaSungen Bioscience Co. Ltd., Shantou, ChinaAntithrombotic & Thrombolytic Innovative Drug Research Center, Shenyang Pharmaceutical University, Shenyang, ChinaDepartment of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaThe Central Laboratory, First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, ChinaSchool of Life Sciences, University of Technology Sydney, Sydney, NSW, AustraliaNattokinase (NK), known as a potent fibrinolytic and antithrombotic agent, has been shown to have antiatherosclerotic and lipid-lowering effects. However, data on human clinical studies are limited. In this clinical study involving 1,062 participants, our objective was to examine the efficacy of NK in atherosclerosis and hyperlipidemia and safety at the dose of 10,800 FU/day after 12 months of oral administration. Various factors, including lower doses that influence NK pharmacological actions, were also investigated. We found that NK at a dose of 10,800 FU/day effectively managed the progression of atherosclerosis and hyperlipidemia with a significant improvement in the lipid profile. A significant reduction in the thickness of the carotid artery intima-media and the size of the carotid plaque was observed. The improvement rates ranged from 66.5 to 95.4%. NK was found to be ineffective in lowering lipids and suppressing atherosclerosis progression at a dose of 3,600 FU/day. The lipid-lowering effect of NK was more prominent in subjects who smoked, drank alcohol, and subjects with higher BMI. Regular exercise further improved the effects of NK. Co-administration of vitamin K2 and aspirin with NK produced a synergetic effect. No noticeable adverse effects associated with the use of NK were recorded. In conclusion, our data demonstrate that atherosclerosis progression and hyperlipidemia can be effectively managed with NK at a dose of 10,800 FU/day. The lower dose of 3,600 FU per day is ineffective. The dose of 10,800 FU/day is safe and well tolerated. Some lifestyle factors and the coadministration of vitamin K2 and aspirin lead to improved outcomes in the use of NK. Our findings provide clinical evidence on the effective dose of NK in the management of cardiovascular disease and challenge the recommended dose of 2,000 FU per day.https://www.frontiersin.org/articles/10.3389/fcvm.2022.964977/fullnattokinaseatherosclerosishyperlipidaemiaanti-atherogenic druglipid lowering effectretrospective study |
| spellingShingle | Hongjie Chen Jiepeng Chen Fuping Zhang Yuanhui Li Ronghua Wang Qiang Zheng Xu Zhang Jun Zeng Feng Xu Yiguang Lin Yiguang Lin Yiguang Lin Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants Frontiers in Cardiovascular Medicine nattokinase atherosclerosis hyperlipidaemia anti-atherogenic drug lipid lowering effect retrospective study |
| title | Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants |
| title_full | Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants |
| title_fullStr | Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants |
| title_full_unstemmed | Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants |
| title_short | Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants |
| title_sort | effective management of atherosclerosis progress and hyperlipidemia with nattokinase a clinical study with 1 062 participants |
| topic | nattokinase atherosclerosis hyperlipidaemia anti-atherogenic drug lipid lowering effect retrospective study |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.964977/full |
| work_keys_str_mv | AT hongjiechen effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT jiepengchen effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT fupingzhang effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT yuanhuili effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT ronghuawang effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT qiangzheng effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT xuzhang effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT junzeng effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT fengxu effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT yiguanglin effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT yiguanglin effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants AT yiguanglin effectivemanagementofatherosclerosisprogressandhyperlipidemiawithnattokinaseaclinicalstudywith1062participants |